

Special Issue

Microbial Antigen Delivery 2.0

Message from the Guest Editors

Historical vaccines based on whole microorganisms, either live attenuated or killed, with their successful long track record for safety and efficacy, are considered one of the most important public health interventions to tackle infectious diseases. However, for many pathogens, there are still no vaccines available. The growing demand for new safer, more efficacious and affordable vaccines has resulted in a shift in research to focus mainly on selected and well characterized antigens and epitopes which are very often low immunogenicity when administered alone. To meet the associated challenges, the knowledge gathered on microbial antigen delivery and their implementation through innovative technologies represent the key points to transforming a low immunogenicity antigen into an efficacious vaccine formulation.

The aim of this Special Issue is to present novel insights and recent advances in the field of microbial antigen delivery, including discovery, development, manufacturing, and regulatory perspectives on new vaccine formulations.

Guest Editors

Prof. Dr. Hosni Hassan

Department of Poultry Science (Microbiology), North Carolina State University, Raleigh, NC 27695, USA

Dr. Epifanio Fichera

Etna Biotech S.r.l, Z.I. Blocco Palma I, Stradale V. Lancia, 57, 95121 Catania, Italy

Deadline for manuscript submissions

closed (10 July 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/62140

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).